CytomX Therapeutics, Inc.

NasdaqGS:CTMX Lagerbericht

Marktkapitalisierung: US$82.0m

CytomX Therapeutics Management

Management Kriterienprüfungen 3/4

CytomX Therapeutics' CEO is Sean McCarthy, appointed in Aug 2011, has a tenure of 13.25 years. total yearly compensation is $2.61M, comprised of 25% salary and 75% bonuses, including company stock and options. directly owns 0.71% of the company’s shares, worth $581.19K. The average tenure of the management team and the board of directors is 3.6 years and 4.8 years respectively.

Wichtige Informationen

Sean McCarthy

Geschäftsführender

US$2.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts25.0%
Amtszeit als Geschäftsführer13.3yrs
Eigentum des Geschäftsführers0.7%
Durchschnittliche Amtszeit des Managements3.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder4.8yrs

Jüngste Management Updates

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

May 09
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

Recent updates

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

Oct 26
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

Jul 15

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Jun 15
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

May 09
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

May 02

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 27
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 25

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

Mar 05
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Jan 19
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Nov 26
There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Nov 17
We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 29
Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Feb 13
Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

CytomX Therapeutics to cut workforce by about 40%

Jul 13

CytomX says phase 2 study of breast cancer antibody treatment met main goal

Jul 06

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Jun 08
Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

Feb 10
Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

CytomX: Pullbacks Are Opportunities

Dec 14

CytomX: Solving A Critical Problem In The High-Value ADC Space

Sep 15

We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Aug 11
We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Sean McCarthy im Vergleich zu den Einnahmen von CytomX Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

US$11m

Mar 31 2024n/an/a

US$17m

Dec 31 2023US$3mUS$652k

-US$569k

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$42m

Mar 31 2023n/an/a

-US$71m

Dec 31 2022US$3mUS$623k

-US$99m

Sep 30 2022n/an/a

-US$149m

Jun 30 2022n/an/a

-US$143m

Mar 31 2022n/an/a

-US$132m

Dec 31 2021US$4mUS$616k

-US$116m

Sep 30 2021n/an/a

-US$72m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$61m

Dec 31 2020US$3mUS$595k

-US$65m

Sep 30 2020n/an/a

-US$54m

Jun 30 2020n/an/a

-US$63m

Mar 31 2020n/an/a

-US$76m

Dec 31 2019US$4mUS$575k

-US$133m

Sep 30 2019n/an/a

-US$99m

Jun 30 2019n/an/a

-US$99m

Mar 31 2019n/an/a

-US$83m

Dec 31 2018US$5mUS$550k

-US$85m

Sep 30 2018n/an/a

-US$52m

Jun 30 2018n/an/a

-US$39m

Mar 31 2018n/an/a

-US$50m

Dec 31 2017US$3mUS$500k

-US$43m

Vergütung im Vergleich zum Markt: Sean's total compensation ($USD2.61M) is above average for companies of similar size in the US market ($USD655.65K).

Entschädigung vs. Einkommen: Sean's compensation has been consistent with company performance over the past year.

Geschäftsführer

Sean McCarthy (57 yo)

13.3yrs

Amtszeit

US$2,611,138

Vergütung

Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since August 2021. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been it...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Sean McCarthy
Chairman & CEO13.3yrsUS$2.61m0.71%
$ 581.2k
Marcia Belvin
Senior VP & Chief Scientific Officer1.8yrsUS$1.21m0.085%
$ 69.8k
Jeffrey Landau
Senior VP3.6yrsUS$1.05m0.079%
$ 65.0k
Christopher Ogden
Chief Financial Officer2.2yrskeine Daten0.039%
$ 31.8k
Lloyd Rowland
Senior VP6.5yrsUS$1.21m0.10%
$ 81.8k
Danielle Olander-Moghadassian
Senior VP & Chief Human Resources Officerno datakeine Datenkeine Daten
Leslie Robbins
Senior Vice President of Intellectual Property5.8yrskeine Datenkeine Daten
Yu-Waye Chu
Chief Medical Officer1.3yrskeine Datenkeine Daten
Dawn Benson
Senior Vice President of Quality & Product Manufacturing1.8yrskeine Datenkeine Daten
Hoyoung Huh
Special Advisor to Chief Executive Officerno dataUS$273.54kkeine Daten

3.6yrs

Durchschnittliche Betriebszugehörigkeit

55.5yo

Durchschnittliches Alter

Erfahrenes Management: CTMX's management team is considered experienced (3.6 years average tenure).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Sean McCarthy
Chairman & CEO13.3yrsUS$2.61m0.71%
$ 581.2k
Elaine Jones
Independent Director5.5yrsUS$75.12k0.0066%
$ 5.4k
John Lambert
Member of Scientific Advisory Board4.8yrskeine Datenkeine Daten
Louis Weiner
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Mani Mohindru
Independent Director3.9yrsUS$78.62k0%
$ 0
James Meyers
Independent Director5.9yrsUS$77.12k0%
$ 0
Matthew Young
Lead Independent Director9.2yrsUS$105.12k0%
$ 0
Halley Gilbert
Independent Director4.6yrsUS$80.62k0%
$ 0
W. Kavanaugh
Member of Scientific Advisory Board3.9yrsUS$8.03mkeine Daten
Alan Ashworth
Independent Director3.2yrsUS$69.12k0%
$ 0
Charles Sentman
Member of Scientific Advisory Board4.8yrskeine Datenkeine Daten
Lisa Coussens
Member of Scientific Advisory Board1.8yrskeine Datenkeine Daten

4.8yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrener Vorstand: CTMX's board of directors are considered experienced (4.8 years average tenure).